Peptides Similar to Oveporexton

Compounds Related to Oveporexton#

Oveporexton (TAK-861) is a first-in-class oral OX2R-selective agonist for narcolepsy type 1. As it targets the orexin system, the most relevant comparisons are with other orexin receptor modulators and established narcolepsy therapies.

Danavorexton (TAK-994)#

Danavorexton (TAK-994) was Takeda's first-generation OX2R-selective agonist, which demonstrated proof of concept for orexin receptor agonism in narcolepsy type 1.

Mechanism comparison: Both danavorexton and oveporexton are small molecule OX2R-selective agonists. However, oveporexton is approximately 10-fold more potent (EC50 2.5 nM vs higher for TAK-994) and has a distinct chemical scaffold.

Efficacy: Danavorexton showed significant improvements in MWT and ESS in a Phase 2 proof-of-concept study, validating the therapeutic approach. Oveporexton confirmed and extended these findings with larger, more robust trials.

Safety: Danavorexton was discontinued due to hepatotoxicity signals detected in Phase 2. Oveporexton has shown no hepatotoxic effects across Phase 2b and Phase 3 trials, representing a critical safety improvement.

Pitolisant (Wakix)#

Pitolisant is an FDA-approved inverse agonist/antagonist at the histamine H3 receptor, approved for excessive daytime sleepiness and cataplexy in narcolepsy.

Mechanism comparison: Pitolisant indirectly promotes wakefulness by blocking presynaptic H3 autoreceptors, thereby increasing histamine release in the brain. Oveporexton directly activates OX2R, the receptor for the neuropeptide deficient in narcolepsy type 1.

Efficacy comparison: In the Phase 2b trial, oveporexton 2 mg BID produced MWT improvements of +23.5 minutes and ESS improvements of -13.8 points. Published pitolisant data show more modest MWT and ESS improvements.

Advantages of pitolisant: FDA-approved since 2019, oral dosing, no hepatotoxicity concerns, once-daily dosing.

Advantages of oveporexton: Targets the specific deficiency in NT1 (orexin signaling), potentially larger effect sizes on wakefulness and cataplexy.

Sodium Oxybate (Xyrem/Xywav)#

Sodium oxybate and its low-sodium formulation (calcium/magnesium/potassium/sodium oxybates, Xywav) are FDA-approved for cataplexy and excessive daytime sleepiness in narcolepsy.

Mechanism comparison: Sodium oxybate acts on GABA-B receptors to consolidate nighttime sleep, which secondarily improves daytime wakefulness. Oveporexton directly activates the wake-promoting OX2R pathway.

Efficacy comparison: Sodium oxybate is considered one of the most effective narcolepsy treatments, particularly for cataplexy. Direct comparison with oveporexton has not been conducted, but oveporexton's Phase 3 cataplexy reductions (more than 80%) are notable.

Key differences: Sodium oxybate requires twice-nightly dosing (at bedtime and 2.5-4 hours later), has abuse potential (Schedule III controlled substance), and has a complex REMS program. Oveporexton is oral twice-daily, showed no abuse potential signals, and would likely not be scheduled.

Modafinil/Armodafinil (Provigil/Nuvigil)#

Modafinil and armodafinil are wake-promoting agents commonly used first-line for excessive daytime sleepiness in narcolepsy.

Mechanism comparison: The exact mechanism of modafinil remains debated but involves dopamine reuptake inhibition and possible orexin system modulation. Oveporexton directly and selectively activates OX2R. Preclinical studies showed that oveporexton's brain activation pattern was more similar to endogenous orexin than modafinil's pattern.

Clinical positioning: Modafinil is first-line for EDS but does not treat cataplexy. Oveporexton addresses both EDS and cataplexy through a single mechanism.

Orexin Receptor Antagonists (Suvorexant, Lemborexant)#

Suvorexant (Belsomra) and lemborexant (Dayvigo) are dual orexin receptor antagonists (DORAs) approved for insomnia. They represent the pharmacological opposite of oveporexton.

Mechanism comparison: DORAs block both OX1R and OX2R to reduce wakefulness and promote sleep. Oveporexton selectively activates OX2R to promote wakefulness. These approaches target opposite ends of the orexin system spectrum.

Clinical significance: The clinical success of DORAs validated the orexin system as a drug target and provided structural biology insights that facilitated OX2R agonist design.

Summary Comparison#

Related Reading#

• Oveporexton overview and research guide
• Oveporexton research evidence
• Oveporexton dosing protocols